ALFA Finder| Revenue growth | 35.3% YoY for Q1 FY27 |
|---|---|
| Margins | EBITDA margin at 20.1% vs 22.7% YoY |
| Demand visibility | Strong IP/OP volumes up 26.6% and 28.5% YoY |
| Management confidence | High; citing 'consistent performer over 2 decades' |
Growth
Revenue grew 35.3% YoY to ₹11,795 Mn. EBITDA increased 20.1% YoY to ₹2,398 Mn, though EBITDA margins contracted to 20.1% due to new unit ramp-ups.
Outlook
Targeting 9600+ bed capacity; added 1300+ beds via Greenfield and O&M. Focus on ramping up Maharashtra and Kerala units.
Risks
PAT fell 56% YoY to ₹374 Mn, impacted by statutory labor code changes and losses from new facility operationalization.
Last quarter's promises, checked
Delivered
- Guided Thane EBITDA break-even by March exit → delivered Neutral (= BEAT)
- Guided 75k ARPOB for Bangalore → delivered ~85k (= BEAT)
- Guided 60% Maharashtra occupancy base → delivered 60.5% (= BEAT)
Partly delivered
- Guided 35-40% Bangalore occupancy by year-end → delivered 20-odd% currently (= PARTIAL)
Missed
- Guided Maharashtra losses narrowing to 6-7cr → delivered higher impact from new units (= MISS)
Investor Presentation filed with BSE, NSE: KIMS. Summary written with AI assistance from the document.
Krishna Institute of Medical Sciences Ltd: key numbers
- Share price
- ₹722.00
- Market cap
- ₹30,324 Cr
- Revenue (annual)
- ₹3,905 Cr
- Net profit (annual)
- ₹241.4 Cr
- P/E (TTM)
- 142.8×Sector 54.5×
- Promoter holding
- 32.66%+0.16% QoQ
- FII holding
- 15.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Krishna Institute of Medical Sciences Ltd
All →Krishna Institute of Medical Sciences Earnings Call Transcript: Key Takeaways
KIMS delivered strong revenue growth led by Kondapur's rapid ramp-up, despite temporary margin compression from new oncology programs.
Krishna Institute of Medical Sciences Other Announcement
KIMS's CARE Ratings monitoring report shows ₹1,311.81 crore of the ₹1,476.45 crore QIP proceeds utilised till Q2 FY27. No deviation from the stated objects was reported.
Krishna Institute of Medical Sciences Management Change
KIMS re-appointed Dr. Abhinay Bollineni as Director & CEO, Dr. Bhaskara Rao Bollineni as CMD, and Ms. Dandamudi Anitha as Whole-time Director. Terms start in 2027.
- Execution
- 5 years
Krishna Institute of Medical Sciences Investor Presentation: Key Takeaways
Q2 FY27 total revenue Rs13,630 Mn (+41.3% YoY), EBITDA Rs2,789 Mn (20.5% margin), PAT Rs757 Mn (+5.1% YoY). Expansion via 700+ beds planned.
Krishna Institute of Medical Sciences Results Update
KIMS reported Q2 FY27 consolidated revenue of Rs 1,363 Crore, up 41.3% YoY, with PAT of Rs 76 Crore. EBITDA rose 34% YoY to Rs 279 Crore.
Krishna Institute of Medical Sciences Q2 FY27 Results: Net Profit ₹74.6 Cr, Up 3.6% YoY
Krishna Institute of Medical Sciences Ltd reported revenue from operations of ₹1,344 Cr (+39.9% YoY) and net profit of ₹74.6 Cr (+3.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹74.6 Cr · +3.6% YoY